Itovebi™ (inavolisib)
for Breast Cancer

Itovebi (inavolisib) is a targeted therapy for HR-positive, HER2-negative metastatic breast cancer with a PIK3CA mutation. Used with palbociclib and fulvestrant, it may double progression-free survival compared to standard treatment. Itovebi works by inhibiting PI3Kα, slowing tumor growth and promoting cancer cell death. It belongs to the PI3K inhibitor class and is taken once daily.

Heart
Other top medicines used to treat Breast Cancer